Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 205

1.

A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer.

Albiges L, Choueiri T, Escudier B, Galsky M, George D, Hofmann F, Lam T, Motzer R, Mulders P, Porta C, Powles T, Sternberg C, Bex A.

Eur Urol. 2015 Jan;67(1):100-10. doi: 10.1016/j.eururo.2014.04.006. Epub 2014 May 1. Review.

PMID:
24841777
2.

Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors.

Turnbull JD, Cobert J, Jaffe T, Harrison MR, George DJ, Armstrong AJ.

Clin Genitourin Cancer. 2013 Mar;11(1):45-50. doi: 10.1016/j.clgc.2012.06.001. Epub 2012 Oct 4.

PMID:
23041453
3.

Retrospective comparison of triple-sequence therapies in metastatic renal cell carcinoma.

Busch J, Seidel C, Erber B, Issever AS, Hinz S, Kempkensteffen C, Magheli A, Miller K, Grünwald V, Weikert S.

Eur Urol. 2013 Jul;64(1):62-70. doi: 10.1016/j.eururo.2012.09.004. Epub 2012 Sep 11.

PMID:
22999519
4.

Combination therapy in metastatic renal cell cancer.

Ravaud A, Gross-Goupil M, Bellmunt J.

Semin Oncol. 2013 Aug;40(4):472-81. doi: 10.1053/j.seminoncol.2013.05.010. Review.

PMID:
23972711
5.

Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: results from a large patient cohort.

Iacovelli R, Cartenì G, Sternberg CN, Milella M, Santoni M, Di Lorenzo G, Ortega C, Sabbatini R, Ricotta R, Messina C, Lorusso V, Atzori F, De Vincenzo F, Sacco C, Boccardo F, Valduga F, Massari F, Baldazzi V, Cinieri S, Mosca A, Ruggeri EM, Berruti A, Cerbone L, Procopio G.

Eur J Cancer. 2013 Jun;49(9):2134-42. doi: 10.1016/j.ejca.2013.02.032. Epub 2013 Mar 18.

PMID:
23518211
6.

Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials.

Coppin C, Kollmannsberger C, Le L, Porzsolt F, Wilt TJ.

BJU Int. 2011 Nov;108(10):1556-63. doi: 10.1111/j.1464-410X.2011.10629.x. Epub 2011 Sep 27. Review.

7.

Treatment patterns in metastatic renal cell carcinoma: a retrospective review of medical records from US community oncology practices.

Jonasch E, Signorovitch JE, Lin PL, Liu Z, Culver K, Pal SK, Scott JA, Vogelzang NJ.

Curr Med Res Opin. 2014 Oct;30(10):2041-50. doi: 10.1185/03007995.2014.938730. Epub 2014 Jul 9.

8.

EAU guidelines on renal cell carcinoma: 2014 update.

Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M, Kuczyk MA, Lam T, Marconi L, Merseburger AS, Mulders P, Powles T, Staehler M, Volpe A, Bex A.

Eur Urol. 2015 May;67(5):913-24. doi: 10.1016/j.eururo.2015.01.005. Epub 2015 Jan 21. Review.

PMID:
25616710
9.

EVERSUN: a phase 2 trial of alternating sunitinib and everolimus as first-line therapy for advanced renal cell carcinoma.

Davis ID, Long A, Yip S, Espinoza D, Thompson JF, Kichenadasse G, Harrison M, Lowenthal RM, Pavlakis N, Azad A, Kannourakis G, Steer C, Goldstein D, Shapiro J, Harvie R, Jovanovic L, Hudson AL, Nelson CC, Stockler MR, Martin A.

Ann Oncol. 2015 Jun;26(6):1118-23. doi: 10.1093/annonc/mdv078. Epub 2015 Feb 20.

PMID:
25701452
10.

Protein kinase inhibitors in renal cell carcinoma.

Daste A, Grellety T, Gross-Goupil M, Ravaud A.

Expert Opin Pharmacother. 2014 Feb;15(3):337-51. doi: 10.1517/14656566.2014.869210. Epub 2013 Dec 16. Review.

PMID:
24328606
11.

Efficacy of targeted therapies after PD-1/PD-L1 blockade in metastatic renal cell carcinoma.

Albiges L, Fay AP, Xie W, Krajewski K, McDermott DF, Heng DY, Dariane C, DeVelasco G, Lester R, Escudier B, Choueiri TK.

Eur J Cancer. 2015 Nov;51(17):2580-6. doi: 10.1016/j.ejca.2015.08.017. Epub 2015 Sep 4.

PMID:
26346135
12.

Characterizing the impact of lymph node metastases on the survival outcome for metastatic renal cell carcinoma patients treated with targeted therapies.

Kroeger N, Pantuck AJ, Wells JC, Lawrence N, Broom R, Kim JJ, Srinivas S, Yim J, Bjarnason GA, Templeton A, Knox J, Bernstein E, Smoragiewicz M, Lee J, Rini BI, Vaishampayan UN, Wood LA, Beuselinck B, Donskov F, Choueiri TK, Heng DY.

Eur Urol. 2015 Sep;68(3):506-15. doi: 10.1016/j.eururo.2014.11.054. Epub 2014 Dec 15.

PMID:
25524810
13.

The role of rechallenge with targeted therapies in metastatic renal-cell carcinoma.

Oudard S, Vano Y.

Curr Opin Urol. 2015 Sep;25(5):402-10. doi: 10.1097/MOU.0000000000000206. Review.

PMID:
26148068
14.

A phase II study of bevacizumab and everolimus as treatment for refractory metastatic renal cell carcinoma.

Harshman LC, Barbeau S, McMillian A, Srinivas S.

Clin Genitourin Cancer. 2013 Jun;11(2):100-6. doi: 10.1016/j.clgc.2012.12.002. Epub 2013 Jan 24.

PMID:
23352238
15.

A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma.

Alimohamed N, Lee JL, Srinivas S, Bjarnason GA, Knox JJ, Mackenzie MJ, Wood L, Vaishampayan UN, Tan MH, Rha SY, Donskov F, Tantravahi S, Kollmannsberger C, North S, Rini BI, Choueiri TK, Heng DY.

Clin Genitourin Cancer. 2014 Aug;12(4):e127-31. doi: 10.1016/j.clgc.2013.12.003. Epub 2013 Dec 27.

PMID:
24485801
16.

Sequencing therapy in metastatic renal cell cancer.

Escudier B, Gore M.

Semin Oncol. 2013 Aug;40(4):465-71. doi: 10.1053/j.seminoncol.2013.05.002. Review.

PMID:
23972710
17.

Sequencing of agents for metastatic renal cell carcinoma: can we customize therapy?

Sonpavde G, Choueiri TK, Escudier B, Ficarra V, Hutson TE, Mulders PF, Patard JJ, Rini BI, Staehler M, Sternberg CN, Stief CG.

Eur Urol. 2012 Feb;61(2):307-16. doi: 10.1016/j.eururo.2011.10.032. Epub 2011 Oct 30. Review.

PMID:
22055147
18.

Inhibition of the VEGF/VEGFR pathway improves survival in advanced kidney cancer: a systematic review and meta-analysis.

Iacovelli R, Sternberg CN, Porta C, Verzoni E, de Braud F, Escudier B, Procopio G.

Curr Drug Targets. 2015;16(2):164-70. Review.

PMID:
25410406
19.

ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease.

Patard JJ, Pignot G, Escudier B, Eisen T, Bex A, Sternberg C, Rini B, Roigas J, Choueiri T, Bukowski R, Motzer R, Kirkali Z, Mulders P, Bellmunt J.

Eur Urol. 2011 Oct;60(4):684-90. doi: 10.1016/j.eururo.2011.06.017. Epub 2011 Jun 24. Review.

PMID:
21704448
20.

Novel agents, combinations and sequences for the treatment of advanced renal cell carcinoma: When is the revolution coming?

Santoni M, Rizzo M, Burattini L, Berardi R, Carteni G, Cascinu S.

Curr Cancer Drug Targets. 2013 Mar;13(3):313-25. Review.

PMID:
23190497

Supplemental Content

Support Center